Wellington Management Group LLP increased its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 7.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 221,236 shares of the company’s stock after purchasing an additional 16,279 shares during the quarter. Wellington Management Group LLP owned 0.39% of Black Diamond Therapeutics worth $473,000 at the end of the most recent quarter. \n\nOther large investors also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new position in Black Diamond Therapeutics in the fourth quarter worth approximately $42,000. Rhumbline Advisers lifted its position in shares of Black Diamond Therapeutics by 14.9% during the 4th quarter. Rhumbline Advisers now owns 56,135 shares of the company’s stock worth $120,000 after purchasing an additional 7,290 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Black Diamond Therapeutics by 46.1% during the 4th quarter. Bank of New York Mellon Corp now owns 207,074 shares of the company’s stock worth $443,000 after purchasing an additional 65,341 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Black Diamond Therapeutics during the fourth quarter worth $53,000. Finally, SLT Holdings LLC purchased a new position in Black Diamond Therapeutics in the fourth quarter valued at $66,000. Hedge funds and other institutional investors own 95.47% of the company’s stock. \n\nBlack Diamond Therapeutics Stock Up 3.6% \n\nShares of NASDAQ BDTX opened at $2.58 on Friday. The business has a 50-day moving average price of $1.76 and a 200 day moving average price of $2.04. The stock has a market cap of $146.71 million, a PE ratio of -1.94 and a beta of 2.63. Black Diamond Therapeutics, Inc. has a 52-week low of $1.20 and a 52-week high of $6.75. \n\nBlack Diamond Therapeutics (<NASDAQ:BDTX> – Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03. Sell-side analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.3 earnings per share for the current year. \n\nInsider Activity \n\nIn other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total value of $11,973,484.44. Following the transaction, the insider now owns 2,733,547 shares of the company’s stock, valued at approximately $5,658,442.29. The trade was a 67.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.97% of the company’s stock. \n\nWall Street Analyst Weigh In \n\nA number of analysts have issued reports on the company. HC Wainwright lifted their price target on Black Diamond Therapeutics from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, March 18th. Stifel Nicolaus decreased their target price on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Wall Street Zen lowered shares of Black Diamond Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $14.60. \n\nBlack Diamond Therapeutics Company Profile \n\nBlack Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.

Wellington Management Group LLP Grows Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Wellington Management Group LLP increased its stake in Black Diamond Therapeutics (BDTX) by 7.9% in Q4, while other institutional investors also adjusted their positions. The company reported Q1 earnings of -$0.28 EPS, exceeding analyst estimates. Insider activity included a significant sale by Growth N.V. Biotech, and analysts issued mixed ratings. BDTX, a clinical-stage oncology biotech, focuses on developing MasterKey therapies for tumors with specific genetic markers.